IRLA · IRulya Therapeutics Inc. · Investor Relations
Substantial doubt about the company's ability to continue as a going concern.
“Factoring in these potential cash payments, based on its current operating plan, the Company believes that its cash and cash equivalents balance will not be sufficient to fund operations and capital expenditures for at least the twelve months following the issuance of these unaudited condensed consolidated financial statements. Accordingly, the Company concluded that substantial doubt about the Company's ability to continue as a going concern continues to exist within one year after the date these financial statements are available to be issued.”View the 10-Q filed Aug 14, 2026
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-10-09 |
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease
Company common stock to trade on Nasdaq under the symbol “IRLA” effective October 12, 2026 Key Management changes include new CEO, Brigette Roberts, M.D.; new CFO, John Militello, CPA; and new COO Keith R. Fandrick, Ph.D. Board strengthened with the addition of Catherine Bonuccelli, M.D., Leone |
| 2026-09-17 |
Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious, underserved diseases, today announced that it will host a virtual key |
| 2026-09-03 |
Quince Therapeutics to Participate in September 2026 Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced that senior management will |
| 2026-08-14 |
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline LAM-001 Phase 2b data in PH-ILD anticipated in the first quarter of 2028; Phase 2 data in BOS anticipated in the first |
| 2026-06-30 |
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board
SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced the formation of a Scientific |
| 2026-05-18 |
Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline
Acquisition includes LAM-001, an inhaled formulation of rapamycin for multiple pulmonary diseases, including pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome post lung transplant (BOS) $115 million in upfront financing with the |
| 2026-05-18 |
Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD
Data from Phase 2a study of LAM-001 on top of standard of care in PH-ILD patients with refractory PH demonstrated clinically meaningful improvement in multiple assessments of lung function, including improvement in 6MWD of 67.4 meters and PVR reduction of 33.9% at 24 weeks Phase 2b trial in PH-ILD |
| 2026-03-30 |
Quince Therapeutics Settles Approximately $16.4 Million of Debt
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 30, 2026-- Quince Therapeutics, Inc. (Nasdaq: QNCX) today announced the successful settlement of the company’s outstanding obligations under its loan from the European Investment Bank (EIB) for a payment of $5.5 million. |
| 2026-02-09 |
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 9, 2026-- Quince Therapeutics, Inc. (Nasdaq: QNCX), today announced that it has engaged LifeSci Capital to serve as its exclusive financial advisor to assist in its restructuring and evaluation of strategic alternatives aimed at maximizing |
| 2026-01-29 |
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
Primary and key secondary endpoint did not achieve statistical significance eDSP was generally well tolerated with no clinically meaningful safety concerns identified Company to cease clinical development of eDSP; Intends to preserve cash and explore available options SOUTH SAN FRANCISCO, Calif. |
| 2026-01-28 |
Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 28, 2026-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the poster presentation of previously published |
| 2025-12-15 |
Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Dec. 15, 2025-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that the last patient has completed their last |
| 2025-12-10 |
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Dec. 10, 2025-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced the publication of a summary of early-stage clinical |
| 2025-11-24 |
Quince Therapeutics to Participate at Investor Events in December 2025
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 24, 2025-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that senior management will participate at |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-09-28 | Quince Therapeutics Virtual KOL Event | Event |
| 2026-09-14 | H.C. Wainwright 28th Annual Global Investment Conference | Conference |
| 2026-09-09 | Cantor Global Healthcare Conference | Conference |
| 2026-06-11 | Quince Therapeutics Inc. 2026 Annual Meeting | Shareholder meeting |
Source: https://ir.quincetx.com/